Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Protara Therapeutics, Inc. Common Stock

TARA

Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.

Last trade $2.32
Day change -$0.06 (-2.52%)
Day range $2.25 – $2.42
Volume 470,882
Market cap $147M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$146.54M
Price / earnings
—
Price / book
1.04×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.43×

Profitability

Earnings per share
-$1.27
Return on assets
-50.11%
Return on equity
-55.63%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.01×
Quick ratio
9.01×
Cash ratio
1.75×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$73.2M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TARA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$6.35M$6.37M$6.07M$5.96M$5.17M$5.82M$4.98M$4.81M
Research and development$16.81M$16.96M$13.56M$13.12M$9.59M$10.77M$9.15M$9.5M
Total operating expenses$23.15M$23.32M$19.63M$19.08M$14.76M$16.59M$14.12M$14.31M
Operating income-$23.15M-$23.32M-$19.63M-$19.08M-$14.76M-$16.59M-$14.12M-$14.31M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$21.69M-$21.67M-$17.78M-$17.31M-$13.26M-$14.96M-$11.91M-$12.77M
Income taxes$0$0$0$0$0$0$0$0
Net income-$21.69M-$21.67M-$17.78M-$17.31M-$13.26M-$14.96M-$11.91M-$12.77M
Net income attributable to common shareholders-$21.69M-$21.67M-$17.78M-$17.31M-$13.26M-$14.96M-$11.91M-$12.77M
EBITDA-$23.08M-$23.25M-$19.54M-$18.99M-$14.67M-$16.49M-$14.04M-$14.23M
Basic earnings per share-$0.35-$0.36-$0.31-$0.38-$0.31-$0.35-$0.29-$0.47
Diluted earnings per share-$0.35-$0.36-$0.31-$0.38-$0.31-$0.35-$0.29-$0.47

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics announced Q3 2026 financial results with $143.1 million in cash and investments. The company expects to complete enrollment of its TARA-002 BCG-Unresponsive registrational cohort by year-end 2026 and complete STARBORN-1 trial enrollment in early Q1 2027, with a rolling BLA submission expected in H2 2027. The company also completed enrollment of the THRIVE-3 Phase 2b trial for IV Choline Chloride and acquired TARA-002 manufacturing assets from Novex Innovations for $8.75 million to bring production in-house.

GlobeNewswire Inc.

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

Protara Therapeutics reported positive 12-month efficacy and safety data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-naïve non-muscle invasive bladder cancer patients, demonstrating a 55% complete response rate at 12 months with no Grade 3 or greater adverse events. The company plans to initiate the registrational ADVANCED-3 trial in the second half of 2026 and submit a BLA for TARA-002 in lymphatic malformations in 2H 2027.

GlobeNewswire Inc.

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Protara Therapeutics reported Q4 2025 results with a net loss of $17.3 million ($0.37 per share) and full-year loss of $57.4 million ($1.34 per share). The company announced interim data from its ADVANCED-2 trial showing TARA-002 achieved a 68% complete response rate at six months in BCG-Unresponsive bladder cancer patients with a favorable safety profile. Protara expects to complete enrollment of the BCG-Unresponsive cohort in H2 2026 and initiate the ADVANCED-3 trial in BCG-Naïve patients in H2 2026. The company also received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations. With $197.9 million in cash and equivalents, Protara expects to fund operations into 2028.

GlobeNewswire Inc.

Protara Therapeutics to Participate in Upcoming Investor Conferences

Protara Therapeutics announced participation in two upcoming investor conferences in February and March 2026, where management will hold fireside chats. The company also plans to present updated interim data from its Phase 2 ADVANCED-2 trial of TARA-002 for BCG-unresponsive non-muscle invasive bladder cancer patients at the ASCO Genitourinary Cancers Symposium.

GlobeNewswire Inc.

Protara Announces Pricing of $75 Million Public Offering

Protara Therapeutics plans to raise approximately $75 million through a public offering of 13,043,479 common stock shares at $5.75 per share, with proceeds intended to fund clinical development of TARA-002 and other programs.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.